{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["taletrectinib"]],"indication":"metastatic and/or unresectable solid tumors","name":"NCT02279433","nct_id":"NCT02279433","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02279433. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"DS-6051b is orally administered as 50 mg and 200 mg capsules once daily on Days 1 to 21 of a 21-day cycle. Dose escalation in Part 1 will continue until tentative Recommended Part 2 Dose (RP2D) is determined. In Part 2 participants will receive the RP2D.","label":"DS-6051b","type":"EXPERIMENTAL"}],"collaborators":["AnHeart Therapeutics Inc."],"completion_date":{"date":"2019-03","type":"ACTUAL"},"conditions":["Solid Tumors"],"enrollment":{"count":46,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"DS6051b","otherNames":["Investigational product","DS-6051a (a free base of 6051b)"],"type":"DRUG"}],"last_update":"2025-06-24","lead_sponsor":"Nuvation Bio Inc.","official_title":"A Phase 1/1B Multi-Center, Non Randomized, Open-Label, Multiple Dose First-In-Human Study Of DS-6051b, An Oral ROS1 And NTRK Inhibitor, In Subjects With Metastatic and/or Unresectable Solid Tumors","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2019-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Part 1: Number of participants with dose-limiting toxicities","timeFrame":"within 21 days following the first dose of treatment"},{"measure":"Tumor response","timeFrame":"up to 2 years"}],"references":[],"start_date":{"date":"2014-09"},"study_type":"INTERVENTIONAL","title":"A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b","url":"https://clinicaltrials.gov/study/NCT02279433"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02279433"}